A Phase 4 interventional study of Omeprazole 20 mg + Sodium Bicarbonate 1100 mg and Omeprazole 20 mg in Heartburn, sponsored by Bayer. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-11.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate a single ingredient product (omeprazole 20 mg) with a combination product capsule (omeprazole 20 mg + sodium bicarbonate 1100 mg) in participants with frequent heartburn.
154 studies on the registry are indexed under Heartburn; 12 are open to participants now.
This study's enrollment of 48 is below the median of 100 across 127 interventional studies indexed under Heartburn.
Browse Heartburn studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.
Drug: Omeprazole 20 mg + Sodium Bicarbonate 1100 mg · Drug: Omeprazole 20 mg
Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.
Drug: Omeprazole 20 mg + Sodium Bicarbonate 1100 mg · Drug: Omeprazole 20 mg
Drug page: Omeprazole
Capsules, orally
Also known as: Zegerid™
Tablets, orally
Also known as: Prilosec OTC™
Time-to-onset of Heartburn Relief
Time-to-onset of heartburn relief was defined as earliest time following start of treatment that participant experienced a reduction of at least one grade from baseline in the severity of heartburn. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows: Absent (0): Heartburn is not present. Mild (1): Heartburn did not last long or was easily tolerated. Moderate (2): Heartburn caused discomfort and interrupted usual activities. Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.
Time frame: Start of treatment until onset of heartburn relief, up to 24 hours
Percentage of Participants Experiencing Onset and Demonstrating Duration of Heartburn Relief Over Time
Onset of heartburn relief was defined as a reduction of at least one grade from baseline in the severity of heartburn following start of treatment. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows: Absent (0): Heartburn is not present. Mild (1): Heartburn did not last long or was easily tolerated. Moderate (2): Heartburn caused discomfort and interrupted usual activities. Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.
Time frame: Start of treatment until onset of heartburn relief, up to 72 hours
Number of Participants Preferring Each Treatment for Heartburn Control: Final Subjective Questionnaire
Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 1 asked participants to compare the 2 treatments for Heartburn Control.
Time frame: At end of study (approx. Study Day 40)
Number of Participants Preferring Each Treatment for Heartburn Relief: Final Subjective Questionnaire
Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 2 asked participants to compare the 2 treatments for Heartburn Relief.
Time frame: At end of study (approx. Study Day 40)
Number of Participants Preferring Each Treatment Overall: Final Subjective Questionnaire
Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 3 asked participants to compare the 2 treatments for their overall preference.
Time frame: At end of study (approx. Study Day 40)
Percentage of Participants Affected By Heartburn Symptoms: End of Treatment Quality of Life Questionnaire
End of Treatment Quality of Life was based on a questionnaire regarding quality-of-life issues associated with heartburn, completed by participants at the end of treatment period 1 and the end of treatment period 2.
Time frame: End of treatment period 1 and end of treatment period 2
| Milestone | Omeprazole 20mg+Sodium Bicarbonate 1100mg Then Omeprazole 20mg | Omeprazole 20mg Then Omeprazole 20mg+Sodium Bicarbonate 1100mg |
|---|---|---|
| Started | 26 | 22 |
| Completed | 26 | 19 |
| Not completed | 0 | 3 |
| Withdrew: Failure to return | 0 | 1 |
| Withdrew: Protocol violation | 0 | 2 |
| Milestone | Omeprazole 20mg+Sodium Bicarbonate 1100mg Then Omeprazole 20mg | Omeprazole 20mg Then Omeprazole 20mg+Sodium Bicarbonate 1100mg |
|---|---|---|
| Started | 26 | 19 |
| Completed | 26 | 19 |
| Not completed | 0 | 0 |
Time-to-onset of heartburn relief was defined as earliest time following start of treatment that participant experienced a reduction of at least one grade from baseline in the severity of heartburn. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows: Absent (0): Heartburn is not present. Mild (1): Heartburn did not last long or was easily tolerated. Moderate (2): Heartburn caused discomfort and interrupted usual activities. Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.
| Minutes | Omeprazole 20 mg + Sodium Bicarbonate 1100 mg | Omeprazole 20 mg |
|---|---|---|
| Time-to-onset of Heartburn Relief | 30.0 (30.0 to 75.0) | 60.0 (30.0 to 105.0) |
Onset of heartburn relief was defined as a reduction of at least one grade from baseline in the severity of heartburn following start of treatment. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows: Absent (0): Heartburn is not present. Mild (1): Heartburn did not last long or was easily tolerated. Moderate (2): Heartburn caused discomfort and interrupted usual activities. Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.
| percentage of participants | Omeprazole 20 mg + Sodium Bicarbonate 1100 mg | Omeprazole 20 mg |
|---|---|---|
| ≤15 minutes | 20.5 | 13.6 |
| ≤30 minutes | 52.3 | 27.3 |
| ≤60 minutes | 75.0 | 61.4 |
| ≤90 minutes | 90.9 | 75.0 |
| ≤120 minutes | 95.5 | 88.6 |
| ≤180 minutes | 100.0 | 90.9 |
| ≤1440 minutes (24 hours) | 100.0 | 93.2 |
| ≤2880 minutes (48 hours) | 100.0 | 95.5 |
| ≤4320 minutes (72 hours) | 100.0 | 100.0 |
Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 1 asked participants to compare the 2 treatments for Heartburn Control.
| participants | All Treated Participants |
|---|---|
| Preferred omeprazole+sodium bicarbonate | 14 |
| Preferred omeprazole | 17 |
| Preferred both equally | 9 |
| Missing data | 8 |
Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 2 asked participants to compare the 2 treatments for Heartburn Relief.
| participants | All Treated Participants |
|---|---|
| Preferred omeprazole+sodium bicarbonate | 16 |
| Preferred omeprazole | 16 |
| Preferred both equally | 7 |
| Preferred neither | 1 |
| Missing data | 8 |
Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 3 asked participants to compare the 2 treatments for their overall preference.
| participants | All Treated Participants |
|---|---|
| Preferred omeprazole+sodium bicarbonate | 17 |
| Preferred omeprazole | 17 |
| Preferred both equally | 6 |
| Missing data | 8 |
End of Treatment Quality of Life was based on a questionnaire regarding quality-of-life issues associated with heartburn, completed by participants at the end of treatment period 1 and the end of treatment period 2.
| percentage of partcipants | Omeprazole 20 mg + Sodium Bicarbonate 1100 mg | Omeprazole 20 mg |
|---|---|---|
| heartburn symptoms affected daily activities | 30.0 | 30.0 |
| heartburn symtoms caused trouble falling asleep | 27.5 | 25.0 |
| heartburn symptoms awoke participant | 22.5 | 32.5 |
| slept on incline due to heartburn symptoms | 35.0 | 47.5 |
| medicine helped with full night's rest | 90.0 | 95.0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Omeprazole 20 mg + Sodium Bicarbonate 1100 mg | — | 0/45 (0%) | 0/45 (0%) |
| Omeprazole 20 mg | — | 0/48 (0%) | 0/48 (0%) |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 48.3 ± 12.57 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 31 |
| Male | 17 |
No study locations are listed for this record.
The record gives a start of Jan 2012, a primary completion of Apr 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omeprazole